SERA PROGNOSTICS REPORTS 3RD QUARTER 2022 FINANCIAL RESULTS.

SALT LAKE CITY: Sera Prognostics Inc., The Pregnancy Company(r) (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter ended September 30, 2022.

Recent Highlights:

Focus on integrated healthcare systems beginning to show success with the signing on of Banner Health, an innovative leader in healthcare models, for its University Family Care/ AHCCCS Complete Care members covered under a Medicaid plan and serving more than 300,000 members. Revenue from these types of integrated healthcare systems could contribute as soon as Q4 2022 and is anticipated to be more meaningful in 2023 and later as more widespread adoption of PreTRM testing occurs.

Announced that Sonrava Health, a national family of health and wellness companies, including Western Dental; and Cerebrae, an innovator in pricing and measuring the financial value of care, are collaborating to provide Sera's PreTRM(r) Test to members of Sonrava Health's employer-sponsored health insurance program. Under a unique platform that leverages actuarial and data science to accurately forecast financial risk and monitor a healthcare solution's performance, Cerebrae's rigorous, third-party analysis supported the inclusion of the PreTRM(r) Test into a Sonrava Health maternity benefits plan.

Executed additional contracts with several new self-insured employer plans to incorporate PreTRM(r) testing as an advanced pregnancy benefit.

Completed the rigorous clinical utility health economic analysis illustrating the impact of Sera's test-and-treat strategy and its specific benefits in underserved racial and ethnic populations, with data under scientific review prior to publication.

Continued progress in building out pipeline, with expected public release of validation of preeclampsia risk prediction for blood drawn at same time as PreTRM(r) test anticipated by year-end 2022.

PRIME study enrollment of patients from 15 centers continuing to enable expected interim look analysis to occur in 2023.

Additional clinical utility data anticipated to be made public as analyses are completed during 2023.

"We are pleased to see our PreTRM(r) Test being supported as a fundamental piece in addressing...